Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis



Status:Completed
Conditions:Arthritis, Rheumatoid Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:18 - 85
Updated:4/2/2016
Start Date:December 2012
End Date:November 2014
Contact:Ram P Singh, MS, Ph.D.
Email:rpsingh@mednet.ucla.edu
Phone:310 267 5749

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

In Vivo Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and Antigen Presenting (APC) Cells in Rheumatoid Arthritis

This proposal will test the hypothesis that Orencia affects apoptosis and apoptosis related
genes/biomarkers in vivo in rheumatoid arthritis (RA) patients.

Orencia may regulate apoptosis and apoptosis related genes in vivo in rheumatoid arthritis
(RA) patient's cells. To date, no studies have been performed to evaluate the effect of
Orencia on apoptosis in RA patients.

Primary: To determine the effect of Abatacept in the apoptosis of T cells, B cells and
antigen presenting cells (APC) in RA patients at baseline, 3 months and 6 months.

Secondary: To evaluate the association between the changes in apoptosis to changes in
disease activity measures (DAS28/ESR) over 6 months of treatment with subcutaneous injection
of abatacept.

Inclusion Criteria:

1. Over age 18

2. Meeting ACR Criteria 1987 for RA diagnosis

3. Naïve to treatment with abatacept

4. Must be able to understand information in the Informed Consent

Exclusion Criteria:

1. Pregnancy or breast feeding

2. Previous exposure to abatacept.

3. History of a concomitant autoimmune disease (eg. SLE, PsA etc.)

4. Patients with history of cancer
We found this trial at
1
site
Univerity of California at Los Angeles
Los Angeles, California 90095
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials